Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900
Donate

5 Important Things to Know About CMS’ Decision to Block Access to Alzheimer’s Treatments

5 Important Things to Know About CMS’ Decision to Block Access to Alzheimer’s Treatments
Share or Print this page
Share or Print this page
April 7, 2023
Share or Print this page

Today marks the one-year anniversary of a unique moment in our country’s health care history. Unfortunately, it is not a celebration: 365 days ago, people living with early Alzheimer’s became the only Americans to be denied access to FDA-approved treatments, thanks to an unprecedented decision made by the Centers for Medicare & Medicaid Services (CMS). One year later, here are 5 important things to know about the impact of this decision and why CMS must immediately reverse it: 
 

1

This is the 1st time in history that Medicare has refused to cover a drug that has been given FDA approval.

2

Each day CMS denies access to FDA-approved Alzheimer’s treatments, more than 2,000 people transition out of eligibility.
 

3

In the last 365 days, more than 730,000 Americans have been denied access to FDA-approved treatments…and as a result, they have also been denied more time with their loved ones.

 

4

More than 100 bipartisan members of Congress have actively called on CMS to reverse their decision.
 

5

People living with Alzheimer’s currently have a 0% survival rate. Now that we have medical breakthroughs, the least we can do is offer those living with Alzheimer’s, a fatal disease, #MoreTime.
 

Join with the Alzheimer’s Association. Use your voice to change this unjust action — click here.

Showing {{currentNumberOfComments}} of {{totalNumberOfComments}} Comments
Post a new comment

Keep Up With Alzheimer’s News and Events

The first survivor of Alzheimer's is out there, but we won't get there without you.

Donate Now

Learn how Alzheimer’s disease affects the brain.

Take the Brain Tour

Don't just hope for a cure. Help us find one. Volunteer for a
clinical trial.

Learn More